Physician profile
Nell E Nestor
NPI 1427023894
$2,307.20
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,260 · 2021: $32.21 · 2022: $14.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $228.91 | 2019 | |
| Pfizer INC. | $192.80 | 2019 | |
| Glaxosmithkline, LLC. | $180.57 | 2019 | |
| Lilly USA, LLC | $177.83 | 2019 | |
| Astellas Pharma US INC | $142.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $140.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.17 | 2019 | |
| Merck Sharp & Dohme LLC | $113.75 | 2019 | |
| Abbvie INC. | $112.06 | 2019-2022 | |
| Amgen INC. | $104.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $103.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $68.46 | 2019 | |
| Horizon Therapeutics Plc | $51.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.42 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $39.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.92 | 2019 | |
| Amarin Pharma, INC. | $31.33 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.88 | 2019 | |
| Daiichi Sankyo INC. | $24.33 | 2019 | |
| Medtronic Vascular, INC. | $19.09 | 2019 | |
| Abbott Laboratories | $18.52 | 2019 | |
| Seqirus USA INC | $14.37 | 2019 | |
| Ibsa Pharma INC. | $14.06 | 2019 | |
| Gilead Sciences, INC. | $13.86 | 2019 | |
| Boston Scientific Corporation | $13.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.23 | 2019 | |
| Allergan, INC. | $12.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nell Nestor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.